Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bulcan.2018.03.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report.
Front Oncol
December 2024
Department of Medical Oncology, International Ward, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China.
Background: ROS1, a member of the sevenless subfamily of tyrosine kinase insulin receptors, promotes tumor cell survival, proliferation, and metastasis by activating the JAK/STAT, PI3K/AKT, and MAPK/ERK pathways. It only accounts for about 2% of total NSCLC cases. No cases of acquired ROS-1 rearrangement have been reported worldwide.
View Article and Find Full Text PDFCase Series: EGFR and ROS-1 Co-Occurrence in Advanced Non-Small Cell Lung Cancer.
J Immunother Precis Oncol
November 2024
Department of Oncology, Princess Norah Oncology Center, King Abdulaziz Medical City, Jeddah, Saudi Arabia.
Non-small cell lung cancer (NSCLC) is a heterogeneous disease with diverse molecular alterations. Two of the most common genetic abnormalities found in advanced NSCLC are mutations in the epidermal growth factor receptor () and rearrangements in the ROS proto-oncogene 1 (). Although these two alterations are typically mutually exclusive, there have been reports of their co-occurrence in a small subset of NSCLC patients.
View Article and Find Full Text PDFExceptional long term response to crizotinib in ROS 1-postive advanced non small cell lung cancer.
Respirol Case Rep
September 2024
Department of Medical Oncology, Amrita Institute of Medical Science and Research Centre Amrita Vishwa Vidyapeetham Kochi India.
Non-small-cell lung cancer (NSCLC) accounts for the majority of lung cancer cases worldwide, with a significant proportion of patients harbouring actionable oncogenic alterations. Among these alterations, the ROS1 rearrangement represents a distinct subset with therapeutic implications. Here, we present the case of a 52-year-old man diagnosed with advanced NSCLC harbouring the ROS1 fusion gene.
View Article and Find Full Text PDFSurvival among patients with lung cancer managed at a tertiary care center in North India.
Monaldi Arch Chest Dis
July 2024
Department of Pulmonary, Critical Care and Sleep Medicine, ESI-PGIMSR, Basaidarapur, New Delhi.
Article Synopsis
- * The study involved primarily male patients (78.26%), with a significant portion being current or former smokers (75%), and a majority suffering from non-small cell lung cancer (86.95%).
- * Findings revealed that the overall mean survival was 12.7 months, with better survival rates in stage IV due to targeted therapy and immunotherapy, highlighting the importance of molecular analysis for optimizing treatment in eligible patients.
Genomic testing and targeted therapy of non-small cell lung cancer in China: a nationwide survey of physicians and clinical pathologists.
Ann Palliat Med
March 2024
Department of Medical Affairs Pfizer Investment Ltd., Chengdu, China.
Background: Genomic diagnostic testing is necessary to guide optimal treatment for non-small cell lung cancer (NSCLC) patients. The proportion of NSCLC patients whose treatment was selected based on genomic testing is still unknown in many countries or needs further improvement. This survey aimed to assess perception of genomic testing and targeted therapy for NSCLC in clinical pathologists and physicians across China.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!